232 related articles for article (PubMed ID: 28783771)
1. PURLs: Direct oral anticoagulants or warfarin for A fib?
Lyon C; Reed A; Prasad S
J Fam Pract; 2017 Aug; 66(8):518-519. PubMed ID: 28783771
[TBL] [Abstract][Full Text] [Related]
2. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Marcy TR; Truong T; Rai A
Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
[TBL] [Abstract][Full Text] [Related]
3. Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review.
Nasser MF; Jabri A; Gandhi S; Rader F
Am J Med; 2021 Dec; 134(12):1465-1475. PubMed ID: 34403701
[TBL] [Abstract][Full Text] [Related]
4. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
5. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
Kubli KA; Snead JA; Cheng-Lai A
Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
[TBL] [Abstract][Full Text] [Related]
6. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Arepally GM; Ortel TL
Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
[TBL] [Abstract][Full Text] [Related]
7. Warfarin pharmacogenetics in the era of new oral anticoagulants.
Wright GE
Clin Genet; 2015 Aug; 88(2):135-6. PubMed ID: 25970639
[No Abstract] [Full Text] [Related]
8. [The ENGAGE AF-TIMI 48 study].
Rubboli A; Colonna P
G Ital Cardiol (Rome); 2015 Sep; 16(9):457-61. PubMed ID: 26418383
[No Abstract] [Full Text] [Related]
9. Meta-analysis of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Bioprosthetic Valves.
Kheiri B; Przybylowicz R; Simpson TF; Alhamoud H; Osman M; Dalouk K; Nazer B; Henrikson CA; Stecker E
Am J Cardiol; 2021 Mar; 142():140-141. PubMed ID: 33285096
[No Abstract] [Full Text] [Related]
10. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
11. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?
Hajhosseiny R; Sabir I; Lip GY
Hosp Pract (1995); 2014 Oct; 42(4):153-62. PubMed ID: 25502139
[TBL] [Abstract][Full Text] [Related]
12. Overview of the new oral anticoagulants: opportunities and challenges.
Yeh CH; Hogg K; Weitz JI
Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
Chen J; Zhuang X; Long M; Su C; Wang L
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
Preblick R; Kwong WJ; White RH; Goldhaber SZ
Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic testing and response to warfarin.
Wu AH
Lancet; 2015 Jun; 385(9984):2231-2. PubMed ID: 25769360
[No Abstract] [Full Text] [Related]
16. Novel anticoagulants for stroke prevention in patients with atrial fibrillation.
Jalota A; Scarabelli TM; Saravolatz L; Bakhsh MU; Agrawal P; Jalota R; Chen-Scarabelli C; Fuster V; Halperin J
Cardiovasc Drugs Ther; 2014 Jun; 28(3):247-62. PubMed ID: 24842559
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?
Plitt A; Giugliano RP
Future Cardiol; 2014 Mar; 10(2):153-5. PubMed ID: 24762238
[No Abstract] [Full Text] [Related]
18. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Xiang CL; Gong YZ; Zeng LJ; Wang R; Kea S; Chaudhary N; Tu RH; He Y
Acta Cardiol; 2016 Jun; 71(3):349-57. PubMed ID: 27594130
[No Abstract] [Full Text] [Related]
20. Comparative effectiveness of warfarin and new anticoagulants.
Adam SS; Ortel TL; Williams JW
Ann Intern Med; 2013 Apr; 158(8):637-8. PubMed ID: 23588759
[No Abstract] [Full Text] [Related]
[Next] [New Search]
